Mike80 personal page - To The Moon

Mike80

Mike80

No personal profile

13Follow

0Followers

0Topic

0Badge

2021-06-15

Good

@格隆汇:維亞生物發佈全年業績，內生增長+外延發展助推收入翻倍

2021-06-15

So so but great prospect

My 3 Favorite Stocks Right Now

2021-06-15

Good sharing

IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings

2021-06-15

Vaccine right and stock to move to right high rise soon

Sorry, the original content has been removed

2021-06-15

Expecting...

What to Expect in This Week’s Federal Reserve Meeting

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3586688746625767,"uuid":"3586688746625767","gmtCreate":1623594723432,"gmtModify":1623730888730,"name":"Mike80","pinyin":"mike80","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":13,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.26","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":187022387,"gmtCreate":1623731329149,"gmtModify":1704209840478,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187022387","repostId":"344346040","repostType":1,"repost":{"id":344346040,"gmtCreate":1618380651780,"gmtModify":1704709933689,"author":{"id":"39105730803552","authorId":"39105730803552","name":"格隆汇","avatar":"https://static.tigerbbs.com/8774dfe20eceb38c9645128bb6e60684","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"維亞生物發佈全年業績，內生增長+外延發展助推收入翻倍","htmlText":"3月30號，維亞生物科技控股集團公佈了截至2020年12月31日的年度業績報告，並召開了年度業績發佈會。報告期內，維亞生物(1873.HK)錄得總收入近7億元，同比上漲超過115%；毛利超過3億元，同比上漲超過95%；經調整後Non-IFRS淨利潤達2.52億元人民幣。其中，來自CFS業務的收入超過6億元，同比增長了146%；同時，CFS業務錄得淨利潤1.66億元，同比大增近45%；來自EFS業務的收入超過9000萬元，同比增長近20%；內生增長疊加外延併購，推動營收與客戶數量雙增長商業模式方面，維亞生物CFS(服務換現金)業務與EFS(服務換股權)業務的協同效益在2020年中得到了進一步的顯現。CFS與EFS業務的齊頭並進使得公司既可以通過藥物研發在短期獲得穩定的服務費現金流，又可以通過藥物項目的孵化在長期獲得投資收益。報告期內，維亞生物CFS業務收入同比大幅增長近150%至6億元以上，客戶數量超過1250家。其中，CFS-藥物發現服務客戶近550家，客戶囊括全球十大製藥公司以及名列Fierce Biotech’s Fierce 15的35家公司，且客戶留存率超過85%；CFS-CDMO業務(朗華)客戶超過700家，前十大客戶留存率更是達到了100%。EFS業務收入同比增長了近20%至9230萬元。2020年，維亞生物共審閱了超過800個早期項目；新增生物醫藥初創企業投資21家；完成了對10家已有孵化企業的追加投資。截至2020年12月31日，維亞生物總計投資孵化了67家生物醫藥初創公司，平均協議持股比例近20%。同時，孵化公司的在研管線共125條，研發進展順利，半數以上管線已進入PCC/IND-enabling階段，11條管線已進入臨牀階段。維亞生物在基於結構的新藥研發技術(SBDD)、基於片段的新藥發現技術(FBDD)、膜蛋白靶點新藥研發技術、以及基於親和力的化合物庫","listText":"3月30號，維亞生物科技控股集團公佈了截至2020年12月31日的年度業績報告，並召開了年度業績發佈會。報告期內，維亞生物(1873.HK)錄得總收入近7億元，同比上漲超過115%；毛利超過3億元，同比上漲超過95%；經調整後Non-IFRS淨利潤達2.52億元人民幣。其中，來自CFS業務的收入超過6億元，同比增長了146%；同時，CFS業務錄得淨利潤1.66億元，同比大增近45%；來自EFS業務的收入超過9000萬元，同比增長近20%；內生增長疊加外延併購，推動營收與客戶數量雙增長商業模式方面，維亞生物CFS(服務換現金)業務與EFS(服務換股權)業務的協同效益在2020年中得到了進一步的顯現。CFS與EFS業務的齊頭並進使得公司既可以通過藥物研發在短期獲得穩定的服務費現金流，又可以通過藥物項目的孵化在長期獲得投資收益。報告期內，維亞生物CFS業務收入同比大幅增長近150%至6億元以上，客戶數量超過1250家。其中，CFS-藥物發現服務客戶近550家，客戶囊括全球十大製藥公司以及名列Fierce Biotech’s Fierce 15的35家公司，且客戶留存率超過85%；CFS-CDMO業務(朗華)客戶超過700家，前十大客戶留存率更是達到了100%。EFS業務收入同比增長了近20%至9230萬元。2020年，維亞生物共審閱了超過800個早期項目；新增生物醫藥初創企業投資21家；完成了對10家已有孵化企業的追加投資。截至2020年12月31日，維亞生物總計投資孵化了67家生物醫藥初創公司，平均協議持股比例近20%。同時，孵化公司的在研管線共125條，研發進展順利，半數以上管線已進入PCC/IND-enabling階段，11條管線已進入臨牀階段。維亞生物在基於結構的新藥研發技術(SBDD)、基於片段的新藥發現技術(FBDD)、膜蛋白靶點新藥研發技術、以及基於親和力的化合物庫","text":"3月30號，維亞生物科技控股集團公佈了截至2020年12月31日的年度業績報告，並召開了年度業績發佈會。報告期內，維亞生物(1873.HK)錄得總收入近7億元，同比上漲超過115%；毛利超過3億元，同比上漲超過95%；經調整後Non-IFRS淨利潤達2.52億元人民幣。其中，來自CFS業務的收入超過6億元，同比增長了146%；同時，CFS業務錄得淨利潤1.66億元，同比大增近45%；來自EFS業務的收入超過9000萬元，同比增長近20%；內生增長疊加外延併購，推動營收與客戶數量雙增長商業模式方面，維亞生物CFS(服務換現金)業務與EFS(服務換股權)業務的協同效益在2020年中得到了進一步的顯現。CFS與EFS業務的齊頭並進使得公司既可以通過藥物研發在短期獲得穩定的服務費現金流，又可以通過藥物項目的孵化在長期獲得投資收益。報告期內，維亞生物CFS業務收入同比大幅增長近150%至6億元以上，客戶數量超過1250家。其中，CFS-藥物發現服務客戶近550家，客戶囊括全球十大製藥公司以及名列Fierce Biotech’s Fierce 15的35家公司，且客戶留存率超過85%；CFS-CDMO業務(朗華)客戶超過700家，前十大客戶留存率更是達到了100%。EFS業務收入同比增長了近20%至9230萬元。2020年，維亞生物共審閱了超過800個早期項目；新增生物醫藥初創企業投資21家；完成了對10家已有孵化企業的追加投資。截至2020年12月31日，維亞生物總計投資孵化了67家生物醫藥初創公司，平均協議持股比例近20%。同時，孵化公司的在研管線共125條，研發進展順利，半數以上管線已進入PCC/IND-enabling階段，11條管線已進入臨牀階段。維亞生物在基於結構的新藥研發技術(SBDD)、基於片段的新藥發現技術(FBDD)、膜蛋白靶點新藥研發技術、以及基於親和力的化合物庫","images":[{"img":"https://static.tigerbbs.com/12391161162a76fa321bc301dcdb79c3"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344346040","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":77,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187023841,"gmtCreate":1623731230883,"gmtModify":1704209835455,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"So so but great prospect","listText":"So so but great prospect","text":"So so but great prospect","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187023841","repostId":"1167323938","repostType":4,"repost":{"id":"1167323938","pubTimestamp":1623723810,"share":"https://www.laohu8.com/m/news/1167323938?lang=&edition=full","pubTime":"2021-06-15 10:23","market":"us","language":"en","title":"My 3 Favorite Stocks Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1167323938","media":"Motley Fool","summary":"These companies make good long-term core holdings.\nStock investing starts with picking the right com","content":"<p>These companies make good long-term core holdings.</p>\n<p>Stock investing&nbsp;starts with picking the right companies. Remember, finding the nextmeme stockbefore the price takes off and selling at the high point is virtually impossible without a time machine.</p>\n<p>Instead, I like buying shares in high-quality companies with strong market positions that have competitive advantages that aren't easily duplicated. Granted, this is easier said than done, but these companies fit the description.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/effed739609f2c132bbfba134fe0ff19\" tg-width=\"2000\" tg-height=\"1333\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>1. Amazon</b></p>\n<p><b>Amazon</b>&nbsp;(NASDAQ:AMZN)&nbsp;has become synonymous with e-commerce, but the company is much more than that. It has done this by sticking to its principles, which include focusing on the customer, innovating, and planning for the long term. You can see this through its popular Amazon Prime subscription service, which includes delivery charges, and hardware devices like Alexa and Kindle. There is also its fast-growing, higher-margin Amazon Web Services (AWS) business that provides cloud computing services.</p>\n<p>Its presence is so dominant that Amazon completely changes an industry's dynamics when it decides to enter the fray. That's because it often provides cheap prices and fast delivery -- a compelling proposition. This happened when it pushed further into selling food and apparel, for instance. The company is also moving further into&nbsp;offering prescription drugs.</p>\n<p>While its long-term focus means Amazon is willing to forgo short-term profits, the company is hugely profitable. Its operating profit grew from 2016's $4.2 billion to $22.9 billion last year. In the first quarter, the company's profit more than doubled from $4 billion to $8.8 billion.</p>\n<p><b>2. Costco</b></p>\n<p><b>Costco Wholesale</b>&nbsp;(NASDAQ:COST)&nbsp;has created quite a shopping experience. Known for its wide aisles, bulk items, and free samples, it has built a loyal and growing membership.</p>\n<p>Costco's simple formula is hard to replicate: It focuses on high-quality merchandise and services, and sells them at low unit prices. Costco's paid members have grown from 47.6 million in 2016 to 58.1 million last year (the fiscal year ends on June 30). Meanwhile, its retention rate has hovered around 90%.</p>\n<p>With a focus on customer needs, it even has a generous return policy to help members have confidence in their purchases.</p>\n<p>Management also keeps an eye on improving results. It has had positive same-store sales (comps) for many years, including a 9% increase last year after excluding the effects of gasoline price changes and foreign currency exchange translation. Operating income grew from $3.7 billion to $5.4 billion over the last five years.</p>\n<p>Recent results also provide encouragement that management continues to execute. Comps increased by 15.2% for the first three quarters of 2021, and operating income grew by more than 26% to $4.4 billion.</p>\n<p>While income investors can find higher yields than Costco's 0.8%, it does have a history of annually raising dividends. This includes increasing May's payment to $0.79 from the previous quarter's $0.70. But better still, the board of directors has declared large special dividends every few years. The most recent was a $10 payment last December.</p>\n<p><b>3. Walmart</b></p>\n<p><b>Walmart</b>&nbsp;(NYSE:WMT)&nbsp;has built itself into the world's largest retailer, serving more than 240 million customers every week. The company, which opened its first discount store nearly six decades ago, squeezes costs and passes these savings on to the customer. This allows Walmart to offer the lowest prices on its goods, making it difficult for competitors to keep up.</p>\n<p>It isn't sitting still, either. It is keeping pace with online competitors, namely Amazon, by investing in technology to provide a seamless omnichannel experience to its shoppers. This includes launching the subscription service Walmart+, which provides delivery, gasoline discounts, and faster checkout at its stores.</p>\n<p>Last year, its adjusted revenue rose by 7.7% to $564.2 billion, driving operating income 9.3% higher to $23.4 billion. In the first quarter, revenue growth was about 2%, and management expects a low-single-digit percentage increase for the year. Its guidance calls for flattish operating income.</p>\n<p>While this outlook undoubtedly disappointed some investors, I'm not concerned. Management has its eyes on the long-term picture, and it is investing in technology to better serve its customers and remain a dominant retailer.</p>\n<p>Walmart also offers a 1.6% yield, and it has also raised its quarterly dividend annually since initiating a payout in 1974. Already aDividend Aristocrat, it will become a Dividend King when the streak hits 50 years.</p>\n<p>While these are three different companies in various stages, each is a strong addition to your portfolio. Adding them will give you a high-growth stock, a steady grower that tends to pay large dividends every few years, and a dominant retailer that continues to grow and regularly increase payments to shareholders.</p>\n<p>That's a winning combination that should make these core holdings a great addition to your portfolio.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>My 3 Favorite Stocks Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMy 3 Favorite Stocks Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 10:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/14/my-3-favorite-stocks-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These companies make good long-term core holdings.\nStock investing starts with picking the right companies. Remember, finding the nextmeme stockbefore the price takes off and selling at the high point...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/14/my-3-favorite-stocks-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","WMT":"沃尔玛","COST":"好市多"},"source_url":"https://www.fool.com/investing/2021/06/14/my-3-favorite-stocks-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167323938","content_text":"These companies make good long-term core holdings.\nStock investing starts with picking the right companies. Remember, finding the nextmeme stockbefore the price takes off and selling at the high point is virtually impossible without a time machine.\nInstead, I like buying shares in high-quality companies with strong market positions that have competitive advantages that aren't easily duplicated. Granted, this is easier said than done, but these companies fit the description.\nIMAGE SOURCE: GETTY IMAGES.\n1. Amazon\nAmazon (NASDAQ:AMZN) has become synonymous with e-commerce, but the company is much more than that. It has done this by sticking to its principles, which include focusing on the customer, innovating, and planning for the long term. You can see this through its popular Amazon Prime subscription service, which includes delivery charges, and hardware devices like Alexa and Kindle. There is also its fast-growing, higher-margin Amazon Web Services (AWS) business that provides cloud computing services.\nIts presence is so dominant that Amazon completely changes an industry's dynamics when it decides to enter the fray. That's because it often provides cheap prices and fast delivery -- a compelling proposition. This happened when it pushed further into selling food and apparel, for instance. The company is also moving further into offering prescription drugs.\nWhile its long-term focus means Amazon is willing to forgo short-term profits, the company is hugely profitable. Its operating profit grew from 2016's $4.2 billion to $22.9 billion last year. In the first quarter, the company's profit more than doubled from $4 billion to $8.8 billion.\n2. Costco\nCostco Wholesale (NASDAQ:COST) has created quite a shopping experience. Known for its wide aisles, bulk items, and free samples, it has built a loyal and growing membership.\nCostco's simple formula is hard to replicate: It focuses on high-quality merchandise and services, and sells them at low unit prices. Costco's paid members have grown from 47.6 million in 2016 to 58.1 million last year (the fiscal year ends on June 30). Meanwhile, its retention rate has hovered around 90%.\nWith a focus on customer needs, it even has a generous return policy to help members have confidence in their purchases.\nManagement also keeps an eye on improving results. It has had positive same-store sales (comps) for many years, including a 9% increase last year after excluding the effects of gasoline price changes and foreign currency exchange translation. Operating income grew from $3.7 billion to $5.4 billion over the last five years.\nRecent results also provide encouragement that management continues to execute. Comps increased by 15.2% for the first three quarters of 2021, and operating income grew by more than 26% to $4.4 billion.\nWhile income investors can find higher yields than Costco's 0.8%, it does have a history of annually raising dividends. This includes increasing May's payment to $0.79 from the previous quarter's $0.70. But better still, the board of directors has declared large special dividends every few years. The most recent was a $10 payment last December.\n3. Walmart\nWalmart (NYSE:WMT) has built itself into the world's largest retailer, serving more than 240 million customers every week. The company, which opened its first discount store nearly six decades ago, squeezes costs and passes these savings on to the customer. This allows Walmart to offer the lowest prices on its goods, making it difficult for competitors to keep up.\nIt isn't sitting still, either. It is keeping pace with online competitors, namely Amazon, by investing in technology to provide a seamless omnichannel experience to its shoppers. This includes launching the subscription service Walmart+, which provides delivery, gasoline discounts, and faster checkout at its stores.\nLast year, its adjusted revenue rose by 7.7% to $564.2 billion, driving operating income 9.3% higher to $23.4 billion. In the first quarter, revenue growth was about 2%, and management expects a low-single-digit percentage increase for the year. Its guidance calls for flattish operating income.\nWhile this outlook undoubtedly disappointed some investors, I'm not concerned. Management has its eyes on the long-term picture, and it is investing in technology to better serve its customers and remain a dominant retailer.\nWalmart also offers a 1.6% yield, and it has also raised its quarterly dividend annually since initiating a payout in 1974. Already aDividend Aristocrat, it will become a Dividend King when the streak hits 50 years.\nWhile these are three different companies in various stages, each is a strong addition to your portfolio. Adding them will give you a high-growth stock, a steady grower that tends to pay large dividends every few years, and a dominant retailer that continues to grow and regularly increase payments to shareholders.\nThat's a winning combination that should make these core holdings a great addition to your portfolio.","news_type":1},"isVote":1,"tweetType":1,"viewCount":141,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187062470,"gmtCreate":1623731012690,"gmtModify":1704209827654,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good sharing&nbsp;","listText":"Good sharing&nbsp;","text":"Good sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187062470","repostId":"1175897310","repostType":4,"repost":{"id":"1175897310","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623725513,"share":"https://www.laohu8.com/m/news/1175897310?lang=&edition=full","pubTime":"2021-06-15 10:51","market":"us","language":"en","title":"IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=1175897310","media":"Benzinga","summary":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is ","content":"<p>This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.</p>\n<p><b>AMTD Digital:</b>Asian digital solutions platform&nbsp;<b>AMTD Digital</b>(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.</p>\n<p><b>Molecular Partners:</b>Clinical stage biotechnology company&nbsp;<b>Molecular Partners</b>(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;<b>Novartis</b>(NYSE:NVS) in 2020,<b>Amgen Inc</b>(NASDAQ:AMGN) in 2018 and&nbsp;<b>AbbVie Inc</b>(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.</p>\n<p><b>WalkMe:</b>With a mission to change the way humans interact with technology,<b>WalkMe</b>(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.</p>\n<p>WalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.</p>\n<p><b>Convey Holding:</b>Health care company&nbsp;<b>Convey Holding</b>(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.</p>\n<p><b>Angel Oak Mortgage:</b>Real estate finance company&nbsp;<b>Angel Oak Mortgage</b>(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.</p>\n<p><b>Lyell Immunopharma:</b>Seeking to disrupt the T-cell reprogramming market,<b>Lyell ImmunoPharma</b>(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered with<b>GlaxoSmithKline</b>(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.</p>\n<p>GlaxoSmithKline owns 14% of Lyell and&nbsp;<b>Bristol-MyersSquibb</b>(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.</p>\n<p><b>Verve Therapeutics:</b>Genetic medicine company<b>Verve Therapeutics</b>(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.</p>\n<p><b>Atai Life Sciences:</b>Backedby&nbsp;<b>Palantir Technologies</b>(NYSE:PLTR) and&nbsp;<b>Paypal Holdings</b>(NASDAQ:PYPL) founder Peter Thiel,<b>Atai Life Sciences</b>(NASDAQ:ATAI) could be one of the high profile IPOs of the week.</p>\n<p>The company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.</p>\n<p><b>AiHui Shou International:</b>Pre-owned consumer electronics reseller&nbsp;<b>AiHuiShou International</b>(NYSE: RERE)seeksto give a second life to all idle goods.</p>\n<p>The company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.<b>JD.com</b>(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 10:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.</p>\n<p><b>AMTD Digital:</b>Asian digital solutions platform&nbsp;<b>AMTD Digital</b>(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.</p>\n<p><b>Molecular Partners:</b>Clinical stage biotechnology company&nbsp;<b>Molecular Partners</b>(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;<b>Novartis</b>(NYSE:NVS) in 2020,<b>Amgen Inc</b>(NASDAQ:AMGN) in 2018 and&nbsp;<b>AbbVie Inc</b>(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.</p>\n<p><b>WalkMe:</b>With a mission to change the way humans interact with technology,<b>WalkMe</b>(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.</p>\n<p>WalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.</p>\n<p><b>Convey Holding:</b>Health care company&nbsp;<b>Convey Holding</b>(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.</p>\n<p><b>Angel Oak Mortgage:</b>Real estate finance company&nbsp;<b>Angel Oak Mortgage</b>(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.</p>\n<p><b>Lyell Immunopharma:</b>Seeking to disrupt the T-cell reprogramming market,<b>Lyell ImmunoPharma</b>(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered with<b>GlaxoSmithKline</b>(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.</p>\n<p>GlaxoSmithKline owns 14% of Lyell and&nbsp;<b>Bristol-MyersSquibb</b>(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.</p>\n<p><b>Verve Therapeutics:</b>Genetic medicine company<b>Verve Therapeutics</b>(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.</p>\n<p><b>Atai Life Sciences:</b>Backedby&nbsp;<b>Palantir Technologies</b>(NYSE:PLTR) and&nbsp;<b>Paypal Holdings</b>(NASDAQ:PYPL) founder Peter Thiel,<b>Atai Life Sciences</b>(NASDAQ:ATAI) could be one of the high profile IPOs of the week.</p>\n<p>The company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.</p>\n<p><b>AiHui Shou International:</b>Pre-owned consumer electronics reseller&nbsp;<b>AiHuiShou International</b>(NYSE: RERE)seeksto give a second life to all idle goods.</p>\n<p>The company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.<b>JD.com</b>(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CNVY":"Convey Holding Parent, Inc.","RERE":"万物新生","AOMR":"ANGEL OAK MORTGAGE REIT INC","LYEL":"Lyell Immunopharma, Inc.","WKME":"WalkMe Ltd.","HKD":"尚乘数科","NVS":"诺华","ATAI":"ATAI Life Sciences B.V.*","MOLN":"Molecular Partners AG"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175897310","content_text":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform AMTD Digital(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company Angel Oak Mortgage(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby Palantir Technologies(NYSE:PLTR) and Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","news_type":1},"isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187068895,"gmtCreate":1623730901817,"gmtModify":1704209824578,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Vaccine right and stock to move to right high rise soon","listText":"Vaccine right and stock to move to right high rise soon","text":"Vaccine right and stock to move to right high rise soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187068895","repostId":"2143736088","repostType":4,"isVote":1,"tweetType":1,"viewCount":141,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187085134,"gmtCreate":1623730650628,"gmtModify":1704209814855,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Expecting...","listText":"Expecting...","text":"Expecting...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187085134","repostId":"1138219989","repostType":4,"repost":{"id":"1138219989","pubTimestamp":1623650085,"share":"https://www.laohu8.com/m/news/1138219989?lang=&edition=full","pubTime":"2021-06-14 13:54","market":"us","language":"en","title":"What to Expect in This Week’s Federal Reserve Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1138219989","media":"Barrons","summary":"As the Federal Open Market Committee holds its regular policy meeting this coming week, once again a","content":"<p>As the Federal Open Market Committee holds its regular policy meeting this coming week, once again analysts and investors should flip the Nixon-era cliché and watch what they say, not what they do. What everybody wants to know is whether the panel finally has gotten around to talking about talking about moving away from its ubereasy monetary policy.</p>\n<p>We all know that the FOMC won’t take any substantive steps in terms of its massive securities purchases, which are still running at $120 billion a month. As for its key federal-funds rate target, that’s stuck at 0% to 0.25% (although there’s an outside chance of technical tweaking of some other Fed-administered rates to address the billions in excess cash sloshing around in the money markets).</p>\n<p>We’ll be looking for what’s in the FOMC’s formal policy statement and the panel’s updated Summary of Economic Projections, which will include the amalgam of the committee members’ guesses on key economic gauges, such as gross domestic product, inflation, and unemployment. Most likely, when that is posted&nbsp;on the Fed’s website&nbsp;at 2 p.m. Eastern Daylight Time on Wednesday, most folks will probably head straight for the FOMC’s guesses on the fed-funds rate, and specifically when liftoff from near-zero is finally expected.</p>\n<p>The “dot plot”—or graph of the FOMC members’ consensus guesses—puts the first hike all the way out past 2023. That seems a very long-term forecast, and as John Maynard Keynes famously pointed out, in the long run we’re all dead. Some Fed watchers, such as J.P. Morgan’s chief U.S. economist, Michael Feroli, look for the dots to show a 2023 liftoff.</p>\n<p>The markets, however, already had been pricing in one or more fed-funds rate hikes by 2023. But concurrent with the previously discussed slide in longer-term bond yields, the interest-rate futures markets have effectively priced out one of those short-term rate increases. In addition, the derivatives market now sees the fed-funds rate peaking under 2%, some 0.4 of a percentage point lower than what it had priced in earlier this year, according to analysts for&nbsp;Natixis.</p>\n<p>Long before making any rate hikes, the Fed will begin to lessen its accommodation by slowing its current pace of securities purchases, which consist of $80 billion of Treasuries and $40 billion of agency mortgage-backed securities every month. The trillions that the Federal Reserve and other central banks have created have gone a long way to boost the values of assets, which rose by $5 trillion, to $136.9 trillion, in the first quarter, according to new Fed data released this past week. That includes a $3.2 trillion rise in the value of equities owned by households and a $968 billion rise in their real estate holdings.</p>\n<p>The key criterion for reduced Fed accommodation is whether the monetary authorities see “substantial further progress” toward reaching what they deem as maximum employment, probably a deliberately ambiguous standard.</p>\n<p>But the increase in payrolls appears to be constrained as much by the supply of labor as businesses’ desire to hire. The latest Job Openings and Labor Turnover Survey, or Jolts, showed&nbsp;a record 9.3 million unfilled openings&nbsp;in April. In addition, 384,000 people left their positions that month, bringing the total of voluntary job quitters to a record four million.</p>\n<p>Anecdotal evidence, including some in the Fed’s beige book summary of economic conditions prepared for the coming meeting, suggests that employers aren’t finding enough workers because of generous unemployment compensation. Unusual for a social science such as economics, there will be a real-time experiment to test this hypothesis as 25 states end the extra $300 weekly payment early.</p>\n<p>Jefferies economists Aneta Markowska and Thomas Simons write in a research note that these 25 states account for about a quarter of all the unemployed workers. Ending their extra jobless benefits could boost employment by roughly two million in the next few months, they estimate. Another growth spurt should follow in September and October after the extra unemployment insurance expires in the remaining states; schools reopen—providing free daycare for some would-be workers, especially women; and many office employees return to their desks, they add.</p>\n<p>At that point, the Fed might start talking about actually reducing its massive securities purchases. Given the “taper tantrum” thrown by the markets when the central bank slowed its bond buying in 2013, this Fed will want to disclose how, when, and how fast it plans to slow its pour into the punch bowl. That’s what we’ll be listening for this week.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What to Expect in This Week’s Federal Reserve Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat to Expect in This Week’s Federal Reserve Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 13:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/what-to-expect-in-next-weeks-federal-reserve-meeting-51623457837?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As the Federal Open Market Committee holds its regular policy meeting this coming week, once again analysts and investors should flip the Nixon-era cliché and watch what they say, not what they do. ...</p>\n\n<a href=\"https://www.barrons.com/articles/what-to-expect-in-next-weeks-federal-reserve-meeting-51623457837?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.barrons.com/articles/what-to-expect-in-next-weeks-federal-reserve-meeting-51623457837?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138219989","content_text":"As the Federal Open Market Committee holds its regular policy meeting this coming week, once again analysts and investors should flip the Nixon-era cliché and watch what they say, not what they do. What everybody wants to know is whether the panel finally has gotten around to talking about talking about moving away from its ubereasy monetary policy.\nWe all know that the FOMC won’t take any substantive steps in terms of its massive securities purchases, which are still running at $120 billion a month. As for its key federal-funds rate target, that’s stuck at 0% to 0.25% (although there’s an outside chance of technical tweaking of some other Fed-administered rates to address the billions in excess cash sloshing around in the money markets).\nWe’ll be looking for what’s in the FOMC’s formal policy statement and the panel’s updated Summary of Economic Projections, which will include the amalgam of the committee members’ guesses on key economic gauges, such as gross domestic product, inflation, and unemployment. Most likely, when that is posted on the Fed’s website at 2 p.m. Eastern Daylight Time on Wednesday, most folks will probably head straight for the FOMC’s guesses on the fed-funds rate, and specifically when liftoff from near-zero is finally expected.\nThe “dot plot”—or graph of the FOMC members’ consensus guesses—puts the first hike all the way out past 2023. That seems a very long-term forecast, and as John Maynard Keynes famously pointed out, in the long run we’re all dead. Some Fed watchers, such as J.P. Morgan’s chief U.S. economist, Michael Feroli, look for the dots to show a 2023 liftoff.\nThe markets, however, already had been pricing in one or more fed-funds rate hikes by 2023. But concurrent with the previously discussed slide in longer-term bond yields, the interest-rate futures markets have effectively priced out one of those short-term rate increases. In addition, the derivatives market now sees the fed-funds rate peaking under 2%, some 0.4 of a percentage point lower than what it had priced in earlier this year, according to analysts for Natixis.\nLong before making any rate hikes, the Fed will begin to lessen its accommodation by slowing its current pace of securities purchases, which consist of $80 billion of Treasuries and $40 billion of agency mortgage-backed securities every month. The trillions that the Federal Reserve and other central banks have created have gone a long way to boost the values of assets, which rose by $5 trillion, to $136.9 trillion, in the first quarter, according to new Fed data released this past week. That includes a $3.2 trillion rise in the value of equities owned by households and a $968 billion rise in their real estate holdings.\nThe key criterion for reduced Fed accommodation is whether the monetary authorities see “substantial further progress” toward reaching what they deem as maximum employment, probably a deliberately ambiguous standard.\nBut the increase in payrolls appears to be constrained as much by the supply of labor as businesses’ desire to hire. The latest Job Openings and Labor Turnover Survey, or Jolts, showed a record 9.3 million unfilled openings in April. In addition, 384,000 people left their positions that month, bringing the total of voluntary job quitters to a record four million.\nAnecdotal evidence, including some in the Fed’s beige book summary of economic conditions prepared for the coming meeting, suggests that employers aren’t finding enough workers because of generous unemployment compensation. Unusual for a social science such as economics, there will be a real-time experiment to test this hypothesis as 25 states end the extra $300 weekly payment early.\nJefferies economists Aneta Markowska and Thomas Simons write in a research note that these 25 states account for about a quarter of all the unemployed workers. Ending their extra jobless benefits could boost employment by roughly two million in the next few months, they estimate. Another growth spurt should follow in September and October after the extra unemployment insurance expires in the remaining states; schools reopen—providing free daycare for some would-be workers, especially women; and many office employees return to their desks, they add.\nAt that point, the Fed might start talking about actually reducing its massive securities purchases. Given the “taper tantrum” thrown by the markets when the central bank slowed its bond buying in 2013, this Fed will want to disclose how, when, and how fast it plans to slow its pour into the punch bowl. That’s what we’ll be listening for this week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":187068895,"gmtCreate":1623730901817,"gmtModify":1704209824578,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Vaccine right and stock to move to right high rise soon","listText":"Vaccine right and stock to move to right high rise soon","text":"Vaccine right and stock to move to right high rise soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187068895","repostId":"2143736088","repostType":4,"isVote":1,"tweetType":1,"viewCount":141,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187085134,"gmtCreate":1623730650628,"gmtModify":1704209814855,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Expecting...","listText":"Expecting...","text":"Expecting...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187085134","repostId":"1138219989","repostType":4,"isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187022387,"gmtCreate":1623731329149,"gmtModify":1704209840478,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187022387","repostId":"344346040","repostType":1,"repost":{"id":344346040,"gmtCreate":1618380651780,"gmtModify":1704709933689,"author":{"id":"39105730803552","authorId":"39105730803552","name":"格隆汇","avatar":"https://static.tigerbbs.com/8774dfe20eceb38c9645128bb6e60684","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"維亞生物發佈全年業績，內生增長+外延發展助推收入翻倍","htmlText":"3月30號，維亞生物科技控股集團公佈了截至2020年12月31日的年度業績報告，並召開了年度業績發佈會。報告期內，維亞生物(1873.HK)錄得總收入近7億元，同比上漲超過115%；毛利超過3億元，同比上漲超過95%；經調整後Non-IFRS淨利潤達2.52億元人民幣。其中，來自CFS業務的收入超過6億元，同比增長了146%；同時，CFS業務錄得淨利潤1.66億元，同比大增近45%；來自EFS業務的收入超過9000萬元，同比增長近20%；內生增長疊加外延併購，推動營收與客戶數量雙增長商業模式方面，維亞生物CFS(服務換現金)業務與EFS(服務換股權)業務的協同效益在2020年中得到了進一步的顯現。CFS與EFS業務的齊頭並進使得公司既可以通過藥物研發在短期獲得穩定的服務費現金流，又可以通過藥物項目的孵化在長期獲得投資收益。報告期內，維亞生物CFS業務收入同比大幅增長近150%至6億元以上，客戶數量超過1250家。其中，CFS-藥物發現服務客戶近550家，客戶囊括全球十大製藥公司以及名列Fierce Biotech’s Fierce 15的35家公司，且客戶留存率超過85%；CFS-CDMO業務(朗華)客戶超過700家，前十大客戶留存率更是達到了100%。EFS業務收入同比增長了近20%至9230萬元。2020年，維亞生物共審閱了超過800個早期項目；新增生物醫藥初創企業投資21家；完成了對10家已有孵化企業的追加投資。截至2020年12月31日，維亞生物總計投資孵化了67家生物醫藥初創公司，平均協議持股比例近20%。同時，孵化公司的在研管線共125條，研發進展順利，半數以上管線已進入PCC/IND-enabling階段，11條管線已進入臨牀階段。維亞生物在基於結構的新藥研發技術(SBDD)、基於片段的新藥發現技術(FBDD)、膜蛋白靶點新藥研發技術、以及基於親和力的化合物庫","listText":"3月30號，維亞生物科技控股集團公佈了截至2020年12月31日的年度業績報告，並召開了年度業績發佈會。報告期內，維亞生物(1873.HK)錄得總收入近7億元，同比上漲超過115%；毛利超過3億元，同比上漲超過95%；經調整後Non-IFRS淨利潤達2.52億元人民幣。其中，來自CFS業務的收入超過6億元，同比增長了146%；同時，CFS業務錄得淨利潤1.66億元，同比大增近45%；來自EFS業務的收入超過9000萬元，同比增長近20%；內生增長疊加外延併購，推動營收與客戶數量雙增長商業模式方面，維亞生物CFS(服務換現金)業務與EFS(服務換股權)業務的協同效益在2020年中得到了進一步的顯現。CFS與EFS業務的齊頭並進使得公司既可以通過藥物研發在短期獲得穩定的服務費現金流，又可以通過藥物項目的孵化在長期獲得投資收益。報告期內，維亞生物CFS業務收入同比大幅增長近150%至6億元以上，客戶數量超過1250家。其中，CFS-藥物發現服務客戶近550家，客戶囊括全球十大製藥公司以及名列Fierce Biotech’s Fierce 15的35家公司，且客戶留存率超過85%；CFS-CDMO業務(朗華)客戶超過700家，前十大客戶留存率更是達到了100%。EFS業務收入同比增長了近20%至9230萬元。2020年，維亞生物共審閱了超過800個早期項目；新增生物醫藥初創企業投資21家；完成了對10家已有孵化企業的追加投資。截至2020年12月31日，維亞生物總計投資孵化了67家生物醫藥初創公司，平均協議持股比例近20%。同時，孵化公司的在研管線共125條，研發進展順利，半數以上管線已進入PCC/IND-enabling階段，11條管線已進入臨牀階段。維亞生物在基於結構的新藥研發技術(SBDD)、基於片段的新藥發現技術(FBDD)、膜蛋白靶點新藥研發技術、以及基於親和力的化合物庫","text":"3月30號，維亞生物科技控股集團公佈了截至2020年12月31日的年度業績報告，並召開了年度業績發佈會。報告期內，維亞生物(1873.HK)錄得總收入近7億元，同比上漲超過115%；毛利超過3億元，同比上漲超過95%；經調整後Non-IFRS淨利潤達2.52億元人民幣。其中，來自CFS業務的收入超過6億元，同比增長了146%；同時，CFS業務錄得淨利潤1.66億元，同比大增近45%；來自EFS業務的收入超過9000萬元，同比增長近20%；內生增長疊加外延併購，推動營收與客戶數量雙增長商業模式方面，維亞生物CFS(服務換現金)業務與EFS(服務換股權)業務的協同效益在2020年中得到了進一步的顯現。CFS與EFS業務的齊頭並進使得公司既可以通過藥物研發在短期獲得穩定的服務費現金流，又可以通過藥物項目的孵化在長期獲得投資收益。報告期內，維亞生物CFS業務收入同比大幅增長近150%至6億元以上，客戶數量超過1250家。其中，CFS-藥物發現服務客戶近550家，客戶囊括全球十大製藥公司以及名列Fierce Biotech’s Fierce 15的35家公司，且客戶留存率超過85%；CFS-CDMO業務(朗華)客戶超過700家，前十大客戶留存率更是達到了100%。EFS業務收入同比增長了近20%至9230萬元。2020年，維亞生物共審閱了超過800個早期項目；新增生物醫藥初創企業投資21家；完成了對10家已有孵化企業的追加投資。截至2020年12月31日，維亞生物總計投資孵化了67家生物醫藥初創公司，平均協議持股比例近20%。同時，孵化公司的在研管線共125條，研發進展順利，半數以上管線已進入PCC/IND-enabling階段，11條管線已進入臨牀階段。維亞生物在基於結構的新藥研發技術(SBDD)、基於片段的新藥發現技術(FBDD)、膜蛋白靶點新藥研發技術、以及基於親和力的化合物庫","images":[{"img":"https://static.tigerbbs.com/12391161162a76fa321bc301dcdb79c3"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/344346040","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":77,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187023841,"gmtCreate":1623731230883,"gmtModify":1704209835455,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"So so but great prospect","listText":"So so but great prospect","text":"So so but great prospect","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187023841","repostId":"1167323938","repostType":4,"isVote":1,"tweetType":1,"viewCount":141,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187062470,"gmtCreate":1623731012690,"gmtModify":1704209827654,"author":{"id":"3586688746625767","authorId":"3586688746625767","name":"Mike80","avatar":"https://static.tigerbbs.com/05ef7b48e64eb88c56678f88ec051d60","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good sharing&nbsp;","listText":"Good sharing&nbsp;","text":"Good sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187062470","repostId":"1175897310","repostType":4,"isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}